药师帮(09885.HK)中期股东应占利润同比增258%至7811.7万元

Group 1 - The company reported revenue of approximately 9.843 billion RMB for the six months ending June 30, 2025, representing a year-on-year growth of 11.7% [1] - Profit attributable to owners increased to 78.117 million RMB, a significant year-on-year growth of 258% [1] - Adjusted net profit under non-IFRS was approximately 122 million RMB, reflecting a year-on-year increase of 33.2% [1] Group 2 - The company's gross profit rose by 25.3% to 1.1045 billion RMB, with the gross margin increasing from 10.0% to 11.2% [1] - The growth in gross margin is primarily attributed to strong downstream demand for the company's proprietary brand products, which has led to an expansion in the scale of high-margin business [1]